3 piezas en los últimos 90 días · Economía y finanzas, Salud
“Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.”
Barrons · 20 jul
“What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.”
Ares Caps Private-Credit Fund Redemptions Again as 14% Seek Exits
Barrons · 25 jun